Circulating ceramides as biomarkers of cardiovascular disease: Evidence from phenotypic and genomic studies.
MetadataShow full item record
AbstractThere is a need for new biomarkers of atherosclerotic cardiovascular disease (ACVD), the main cause of death globally. Ceramides, a class of potent bioactive lipid mediators, have signalling roles in apoptosis, cellular stress and inflammation. Recent studies have highlighted circulating ceramides as novel biomarkers of coronary artery disease, type-2 diabetes and insulin resistance. Ceramides are highly regulated by enzymatic reactions throughout the body in terms of their activity and metabolism, including production, degradation and transport. The genetic studies that have been completed to date on the main ceramide species found in circulation are described, highlighting the importance of DNA variants in genes involved in ceramide biosynthesis as key influencers of heritable, circulating ceramide levels. We also review studies of disease associations with ceramides and discuss mechanistic insights deriving from recent genomic studies. The signalling activities of ceramides in vascular inflammation and apoptosis, associations between circulating ceramides and coronary artery disease risk, type-2 diabetes and insulin resistance, and the potential importance of ceramides with regard to ACVD risk factors, such as blood pressure, lipoproteins and lifestyle factors, are also discussed. [Abstract copyright: Copyright © 2021 The Author(s). Published by Elsevier B.V. All rights reserved.]
CitationAtherosclerosis, volume 327, page 18-30
DescriptionFrom PubMed via Jisc Publications Router
History: received 2021-02-28, revised 2021-04-25, accepted 2021-04-30
Publication status: aheadofprint